Insulin Therapy Center

Laurie Klipfel, RN, MSN, BC-ANP, CDE was recently asked if she could offer any pearls of wisdom for another Disaster Averted regarding a patient with type 1 diabetes who couldn't afford his analog insulin. After reading her advice, keep reading to learn how you can take action to help make insulin more affordable.

Greater risk reduction in those not receiving antihyperglycemic treatment.

Most insurance plans will be dropping Lantus from formularies.

A single, once-daily injection to lower both fasting and postprandial blood glucose

Friend of Diabetes in Control and frequent guest author David Kliff, Diabetic Investor, shared his views on some of the news coming out of EASD. As always, his ideas are thought-provoking. We reached out to some of our Advisory Board members to get their responses to David’s piece, and they provided additional strong viewpoints for your consideration.

In Part 2 of this exclusive interview, Dr. Robert Geho discusses the Phase 2b study which focuses on adding Diasome's HDV to a leading pre-meal fast acting analogue.

In part one of this exclusive interview, Dr. Robert Geho discusses the essential role of the liver in metabolizing insulin, and asks why we hear about the artificial pancreas all the time, but never hear anyone talk about an artificial liver?

In this Exclusive Interview, Dr. Robert Geho joins Diabetes in Control publisher Steve Freed at the 2016 Diabetes Symposium in Boston to discuss the testing, affects, and potential marketing of a new insulin delivery system currently undergoing trials. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc. …

In Part 7, the final installment of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho explains the potential marketing and timing of the product offering. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc.  In his role at Diasome, he leads the …

In Part 6 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho and Diabetes in Control publisher Steve Freed discuss the possible reduction in the use of insulin as well  as hypoglycemia following the use of the product. Robert Geho, MD, is a co-founder and CEO …